Picture of BetterLife Pharma logo

BETR BetterLife Pharma Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+13.13%
3m+67.29%
6m+26.1%
1yr+16.43%
Volume Change (%)
10d/3m+55.94%
Price vs... (%)
52w High-12.5%
50d MA+15.64%
200d MA+34.01%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Jan 202431st Jan 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of BetterLife Pharma EPS forecast chart

Profile Summary

BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Company’s subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.

Directors

Last Annual
January 31st, 2023
Last Interim
October 31st, 2023
Incorporated
June 10th, 2002
Public Since
December 19th, 2017
No. of Employees
4
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
113,825,305

BETR Share Price Performance

Upcoming Events for BETR

BetterLife Pharma Inc Annual Shareholders Meeting

Q4 2023 BetterLife Pharma Inc Earnings Release

Q1 2024 BetterLife Pharma Inc Earnings Release

Similar to BETR

Picture of Albert Labs International logo

Albert Labs International

ca flag iconCanadian Securities Exchange

Picture of Algernon Pharmaceuticals logo

Algernon Pharmaceuticals

ca flag iconCanadian Securities Exchange

Picture of Alpha Cognition logo

Alpha Cognition

ca flag iconCanadian Securities Exchange

Picture of Asep Medical Holdings logo

Asep Medical Holdings

ca flag iconCanadian Securities Exchange

Picture of Awakn Life Sciences logo

Awakn Life Sciences

ca flag iconCanadian Securities Exchange

FAQ